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OBJECTIVES: Constipation is considered an inconvenient problem, however data
on the real burden is lacking. The objective of the current analysis was to assess the
clinical and economic burden of chronic constipation in Belgium.METHODS: From
the IMS Hospital Disease Database (year 2007), which includes data on full hospi-
talizations and day clinic for 34.3% of Belgian hospital beds, stays of patients with
constipation were selected based on the ICD-9-CM code (564.0) with constipation as
a primary diagnosis. The database allows to estimate length of stay (LOS), in-
hospital mortality, performed interventions, ATC classified medication usage, and
cost of hospitalisation. Using the 34% coverage, a national projection was made for
the number of hospital stays and burden of disease. 2007 costs were extrapolated to
2010 using progression in costs from 2001 to 2007. ATC codes for osmotic/contact
laxatives, softeners, bulking agents, enemas and peripheral opioid receptor antag-
onists were used. Occurrence of relevant co-morbidities was analyzed using appli-
cable ICD-9-CM codes. RESULTS: There were 6338 hospital day clinic stays and full
hospitalizations (LOS 5.44 days). About 42% of the patients were admitted via the
ER. Most occurring co-morbidities were hemorrhoids (174), fecal impaction (74) and
intestinal obstruction (53). Mortality rate was 0.46% meaning 29 deaths in hospi-
talizations for constipation. Especially in hospitalized patients, usage of enemas
was pronounced (34.17%). Osmotically acting laxatives are the most used agents
(39.58%). The average costs per patient was €1883, consisting of medication costs,
procedural costs and stay costs of €112, €675 and €1097, respectively. Extrapolated
to Belgium the total hospitalization cost for constipation was approximately €11.9
million. Hospital stay is more frequent in the elderly particularly in elderly females.
CONCLUSIONS: Constipation is an underestimated disease condition reflected by
hospital related costs of about €11.9 million and approximately 29 death cases in
Belgium in 2007.
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OBJECTIVES: The aim of this study was to assess disease stage dependent resource
use and costs in chronic genotype 1 hepatitis C (CHC) patients in Belgium.
METHODS: The medical records of 157 CHC patients were reviewed to identify
medical costs over a follow up period of 3 years. Six disease stages were defined
based on histology/clinical data: mild disease (F0-F2), moderate disease (F3) or
compensated cirrhosis without varices (F4), compensated cirrhosis with varices
(F4), decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver trans-
plantation (LT). Data collected were baseline demographic characteristics, HCV-
related data and detailed resource use (hospitalizations, day-clinic visits, surgery/
interventions, physician visits, diagnostic tests and drug use). Resource use items
were multiplied with unit costs (2010) to calculate costs. The public health care
payer’s (HCP) perspective was taken including the health insurance and patient
co-payment. RESULTS: Intravenous/intranasal drug use was reported in circa 20%
of patients, 63% had co-morbidities at study start. Nineteen patients (12%) died
during the study period, whereof 79% attributable to HCV. Average number of
hospitalizations during the study period ranged between 0.4 (mild disease) and 5.3
(HCC). Cost of care during the study period ranged from €18,993 for mild disease (in
81% due to HCV drug treatment) to €35,987 for patients with HCC (in 83% due to
hospitalization, 11% due to medication and in 6% due to ambulatory care) and
€65,120 for patients who underwent a liver transplant (79% hospitalization, 18%
medication, 3% ambulatory care). Cost of diagnosis of the disease stage ranged
between €790 (F3-F4 without varices) and €4142 (decompensated cirrhosis).
CONCLUSIONS: Antiviral treatment is the most important cost driver in mild &
moderate disease, but once complications of CHC occur, the associated costs far
exceed this cost of antiviral therapy.
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OBJECTIVES: Hepatitis C (HCV) is a disease which in the long run can lead to
cirrhosis and liver cancer, resulting in liver transplantation or death if not treated
properly. So far, there is a paucity of literature on health care costs and quality of
life (QoL) of HCV management. This study aims to illustrate the health care costs
and QoL associated with HCV in The Netherlands. METHODS: This study followed
a cross-sectional design for QoL and indirect costs, and a retrospective design for
direct costs (these were mapped retrospectively until 3 years ago or diagnosis of
HCV if earlier). Patients with HCV genotype 1 at Erasmus MC were invited to par-
ticipate between November 2010 and April 2011. Patients were asked to complete
the EQ-5D, Short form 36 (SF-36), Liver disease symptom index (LDSI) and Short
form health and labour questionnaire (SF-HLQ). Resource use data were collected
from the hospital information system. Utilities were determined using the UK tariff
for EQ-5D The Mann-Whitney U-test was used for comparisons between treated
and non-treated patients for the disease categories, mild and moderate disease and
cirrhosis. RESULTS: Thirty-seven patients had either completed or discontinued
treatment during the observation period, 10 had achieved sustained viral response
(SVR). Mean direct costs were higher for treated patients, during all 3 years of
observation; 3286 versus 5361, 1336 versus 9440, 2538 versus 10.507, (p0.01). Com-
pared to non-responders successfully treated patients had lower follow-up costs 1
year after treatment, 1172 versus 1426, and a higher mean utility, 0.84 versus 0.70,
neither result was statistically significant at p0.4 and p0.2. There were no sig-
nificant differences in indirect costs. CONCLUSIONS: This study provides basic
information about the costs and utility of hepatitis C treatment. Such information
is valuable when considering cost-effectiveness of new treatments for this disease.
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OBJECTIVES: As a result of successful treatments for chronic hepatic diseases
(CHDs), patients’ life expectancy, but also the diseases prevalence and costs are
increasing. However, societal costs for CHDs remain little known. We assessed
treatment and productivity costs of patients with CHDs in Italy. METHODS: a nat-
uralistic multicentre Cost-of-Illness study was conducted. Adult patients (age18
years) diagnosed with CHDs, consequently accessing at gastroenterology unit of 2
hospitals, were enrolled. Direct and indirect costs were assessed from the societal
perspective, reported as mean €/patient-month (treatment cost) and mean days/
patient-month of work/school/usual activities lost (productivity loss). The patients
were sub-grouped according to their main condition at the enrollment: hepatitis B,
hepatitis C, cirrhosis, liver transplantation, hepatic carcinoma. RESULTS: We en-
rolled 1,088 valid patients, 62.0% male (N675), aged 19-90 (median60) years:
31.5% (N342) has hepatitis C, 20.3% (N220) cirrhosis, 19.8% (N216) hepatitis B,
11.9% (N129) had liver transplantation, 7.5%(N82) hepatic carcinoma, 9.0%
(N99) had other hepatic diseases. Overall, their treatment cost was 278.26 €/pa-
tient-month: 96% for conventional drug treatment, 4% for unconventional treat-
ment (homeopathy, preparation of herbs, specific diet, multi-vitamin products).
Patients who received liver transplantation were the most expensive (1041.31€/
patient-month), followed by hepatitis B (249 €/month), hepatitis C (167 €/month).
Productivity loss corresponded to 4.9 days/patient-month, mainly by transplanted
patients (8.6 days/patient-month) and those with cirrhosis (8 days/patient-month).
CONCLUSIONS: CHDs sensitively contribute to the high cost and require appropri-
ate health technology valuations to guide stakeholders to find optimal diagnostic
and treatment strategies.
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OBJECTIVES: There is no published study about the direct costs linked to the pro-
cedure of the EC in Brazil. Our aim was to determine a base price of a single
procedure of EC. METHODS: Based on a micro cost approach, we first determined
the individual items that compose an EC procedure. Then we conducted a market
price search for each of them in order to compose the final total cost. For the
permanent equipment needed we considered an amortization time of 24 months
and a 1% monthly interest percent rate. RESULTS: An EC procedure requires an
initial investment in one computer and in one receiver, which is attached to the
patient to capture the capsule’s signal, known as “belt”. Included in the analysis
there are also the cost of the capsule per si, some medicines, the physician’s and
the room fee. The initial investment is US$19,411. Each capsule cost US$647 (single
use). A medical fee of US$380 was set, that include the administration of the cap-
sule, the supervision of the patient during the length of the procedure and the
interpretation of the exam. Considering a service that performs three exams a
month, a cost of US$1645 would be necessary to cover the expenses with material,
personnel (doctors included) and to pay the amortization costs, insurance and
interests for a 24 months period. CONCLUSIONS: In Brazil, the cost of EC procedure
may be set at US$1645 in order to cover the expenses of the services.
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OBJECTIVES: Estimate long-term cost-effectiveness of treatment with peginter-
feron (pegINF) alfa-2a (180 mcg/week) in combination with ribavirin (RBV) (800 –
1200 mcg/day) versus pegINF alfa-2b (1.5 mcg/kg/week) in combination with RBV
(800- 1400 mg/day), in patients with Chronic Hepatitis C (CHC), from the Portuguese
National Health System (NHS) perspective. METHODS: To project disease progres-
sion, a seven-health state Markov model was built based on clinical stages of CHC.
Efficacy data was obtained from a published meta-analysis of 8 head-to-head ran-
domized trials that showed higher sustained virological response (SVR) in patients
receiving pegIFN alfa-2a compared to pegIFN alfa-2b. Effectiveness was measured
in terms of quality-adjusted life years. Transition probabilities and health state
utilities were obtained from published literature. Treatment duration was consid-
ered to be 48 and 24 weeks for genotypes 1/4 and 2/3, respectively. A Delphi panel
with Portuguese experts was conducted to evaluate direct medical resources asso-
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ciated with each health state, followed by micro-costing of the results. Costs were
calculated according to Portuguese official databases. Only direct health costs were
applied. The annual discount rate for costs and outcomes was considered to be 3%,
according to Portuguese guidelines. A deterministic and probabilistic sensitive
analysis was performed. RESULTS: Assuming a lifetime horizon, each patient
gained 0.43, 0.55 and 0.63 life years and 0.17, 0.21 and 0.24 quality-adjusted life
years with pegIFN alfa-2a plus RBV versus pegIFN alfa-2b plus RBV for all CHC
genotypes, genotypes 1/4 and genotypes 2/3 respectively. The savings per patient
treated with pegIFN alfa-2a plus RBV were 44€, 259€ and 1.647€ for all genotypes,
genotypes 1/4 and genotypes 2/3, respectively. CONCLUSIONS: According to the
present model, the treatment of patients with CHC with pegIFN alfa-2a plus RBV is
a dominant strategy in comparison to pegIFN alfa-2b plus RBV for all genotypes,
from the Portuguese NHS perspective.
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OBJECTIVES: Proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and
sucralfate present varying pharmacological efficacy in preventing stress ulcer
bleeding (SUB) in intensive care units. The literature also reports disparate rates of
ventilator assisted pneumonia (VAP) as side-effects of these treatments. We com-
pared the cost-effectiveness of these 3 pharmaco-prophylaxis options. METHODS:
We constructed a decision tree for patients at high-risk for developing SUB (diag-
noses of major trauma, hypovolemic shock, sepsis, septicaemia, acute respiratory
failure, extensive burns, acute renal failure, shock, acute pancreatitis, coronary
artery bypass graft surgery). Probabilities were obtained from a broad literature
search. Costs were estimated using the Nationwide Inpatient Sample 2008, a rep-
resentative US country-wide database and were expressed in 2010 US$. In each of
the 3 treatment branches (PPI, H2RA and sucralfate), patients could be in one of
three states of health: no complication (NC), SUB or VAP. A third-party payer per-
spective was adopted. Cost-effectiveness and sensitivity analyses were performed.
A 60-day time horizon was adopted. RESULTS: PPI, H2RA and sucralfate treatments
were associated with SUB and VAP probabilities of 5.9% and 17.2%, 5.1% and 17.7%,
and 1.4% and 10.3%, respectively. Lengths of stay and per diem costs were 14 days
and $2,993 for NC, 24 days and $2,764 for SUB, and 42 days and $3,310 for VAP.
Average costs per no-rebleeding patient were $58,734 for PPI, $77,543 for H2RA, and
$77,366 for sucralfate. H2RA and Sucralfate were dominated by PPI. These findings
were robust on sensitivity and threshold analyses. Probability of complications
would need to increase to 20% in the PPI group or drop to 1% in either of the other
two treatment groups in order for PPI to cease being the dominant strategy.
CONCLUSIONS: PPI prophylaxis is the dominant prophylactic strategy in patients
at high-risk of developing SUB when compared to using H2RA or sucralfate.
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OBJECTIVES: To undertake a comparative analysis of 2 schemes of TPN: isolated
standard scheme of TPN (2 types: “all in one bag” and “111”) and scheme of TPN,
which includes expenses for purchasing and usage of glutamine dipeptide.
METHODS: Pharmacoeconomic analysis “cost-effectiveness” was provided. The
study estimated direct costs, because appraisal from the stand point of the Russian
healthcare system was chosen: expenses for drug therapy, hospitalization (inten-
sive care unit and medical division) and late complications (pneumonia and sepsis)
treatment. Effectiveness data was taken from clinical trial: Eandi M., Pradelli S.,
Lanazzo S.. Alanyl-glutamine Dipeptide (Dipeptiven) in Total Parenteral Nutrition
(TPN) Therapy in Critically Ill Italian Patients: A Pharmacoeconomic Simulation
Model. AdRes Health Economics and Outcomes Research - Torino (Italy), 2010.
Survival rate of patients was the main effectiveness criterion. Three types of TPN
were compared: “3 in 1” and “111” without glutamine dipeptide usage and “3 in
1” system with glutamine dipeptide. Two-factor sensitivity analysis was carried
out, which showed that results of our pharmacoeconomic study were stable.
RESULTS: In the course of analysis the following results were obtained: direct
medical expenses for 1 patient treatment with TPN system “3 in 1” were 1561,92 €;
“111” – 1651,25 €; “3 in 1” glutamine dipeptide – 1652,66 €. Taking into account
the value of effectiveness rate of 3 compared TPN systems (“3 in 1” and “111” –
0,6554 and “3 in 1” glutamine dipeptide - 0,7624) the results of Cost-Effectiveness
Ratio (CER) were the following: “3 in 1” – 2383,15 €; “111” - 2519,45 € and “3 in 1”
 glutamine dipeptide – 2167,71 €. CONCLUSIONS: According to the results of our
research TPN system “3 in 1” glutamine dipeptide is a dominant alternative as at
the greatest effectiveness rate, CER result is the least of all compared systems.
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OBJECTIVES: The cost-effectiveness of peginterferon and ribavirin (PEG_IFNRBV)
for elderly patients with chronic hepatitis C (CHC) was investigated. A nationwide
registration of interferon-treated hepatitis patients has been conducted in Japan
since 2009. This study was based on individual patient data from the registration
for investigation in a real-world setting. METHODS: PEG_IFNRBV-treated CHC
patients 65-years or older were analyzed. All registered patients received antiviral
treatment, and were assumed to suffer if not treated. The incremental cost and
effectiveness of treatment was estimated as the difference between actual events
and the assumed longstanding disease status. The individual patient data regard-
ing age, gender, and duration of and response to treatment was used to estimate
cost of PEG_IFNRBV, cost of following CHC, and quality-adjusted life-year (QALY).
Incremental cost effectiveness ratio (ICER) and 95% bootstrap confidence interval
(CI) were calculated, and probabilistic sensitivity analysis (PSA) was done for as-
sumptions on the distribution of uncertain data. Conservative assumptions were
used throughout the analysis. RESULTS: There were a total of 1378 patients (me-
dian age 68 y; range 65 – 80 y). 1005 patients had hepatitis C virus type 1 (72.9%), and
1269 had a high viral load (92.1%). A platelet count of 100,000/mm3 was found in
152 patients (11.0%), 100,000 – 150,000/mm3 in 541 patients (39.3%), and 3150,000/
mm3 in 655 patients (47.5%). 1106 patients completed the planned treatment
(80.3%). Sustained viral response was observed in 650 cases (47.2%), relapse in 404
cases (29.3%), and no response in 324 cases (23.5%). Incremental cost was calcu-
lated to be 1.885 million yen (approximately 16,390 euros) for a patient, and effec-
tiveness was 0.657 QALY. ICER was 2.869 million yen (approximately 24,950 euros)/
QALY (95% CI: 2.665 – 3.089 million yen /QALY). PSA showed that most trials had
ICER of less than 4.00 million yen/QALY. CONCLUSIONS: The ICER of PEG_IFNRBV
for elderly patients with CHC seemed acceptable.
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OBJECTIVES: Postoperative infections bring about an expansion of length of hos-
pital stay (LOS) and extra medical costs. METHODS: We analyze the relationship
between variations in antimicrobial prophylaxis (AMP) and extra medical costs in
surgical patients with colorectal malignancies. Utilizing profiling administrative
data, we analyzed 161 admitted patients between 2007 and 2009 to a university
hospital. We classified the patients into two classes based on AMP duration: the
control group (112) and the case group (49). Most patients from both groups were
appropriately given AMP agents consistent with the guidelines of infection-related
associations. RESULTS: The LOS of the control group (24.6 12.1 days) was shorter
than that of the case (49.4  35.2) (p0.05). Hospitalization charge of the control
group (15130  3930 USD) was lower than that of the case (23130  1212) (p0.05),
but hospitalization charge per day of the control group (670 160 USD) was higher
than that of the case (530  130) (p0.05). Furthermore, 73 cases of the control
group were given on the day of surgery till the first postoperative day, and 39 cases
were given to the second and third postoperative days. LOS of the former (22.7 9.5
days) was shorter than that of the latter (28.3 15.5) (p0.05). CONCLUSIONS:AMP
agents in our hospital were found to generally given according to the recom-
mended guidelines. It is important for the hospital administrators to quantify the
additional costs on top of the primary diagnosis in order to properly deal with
infection control and hospital management.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: The aim of this study was to assess adherence and persistence to
mesalamine treatment in ulcerative colitis (UC), and to evaluate the impact on
health care resource utilization and cost from a Canadian health care system
perspective. METHODS: A retrospective prescription and medical claims analysis
was conducted using a random sample of UC patients with no diagnosis of Crohn’s
disease who were initiated on an oral mesalamine formulation from January 2005
to December 2009. Treatment adherence (medication possession ratio [MPR]) and
persistence were calculated over a 1-year period after index prescription. To eval-
uate the economic impact of non-adherence and non-persistence, the number and
all-cause costs of physician visits, emergency visits, and hospitalizations were
estimated. Statistical comparisons, based on adherence and persistence, were
made using the chi-square test for proportions and Student’s t-test or the F-test
from one-way ANOVA for means. Statistical significance was p0.05. RESULTS: A
sample of 1681 patients was obtained. The mean age of new oral mesalamine users
was 55.3 years (SD17.8), with a similar proportion of males and females. At month
12, 27.7% of patients had a MPR 80%, and 45.5% of patients were persistent on
treatment. Over the 12-month period, there was a statistically significant differ-
ence in overall health care resource utilization and all-cause costs in non-persis-
tent ($4973.57) versus persistent ($3256.23) patients to UC medications (p0.001,
unadjusted), with hospitalizations as the major cost driver. Similar numeric differ-
ences were observed for overall health care costs associated with non-adherence
versus adherence ($4357.70 versus $3758.81, p0.277, unadjusted).CONCLUSIONS:
Adherence and persistence to oral mesalamine for the treatment of UC was rela-
tively poor in this patient cohort. Furthermore, patients who were non-persistent
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